


## Original Article

# Productivity Loss Associated with Disability from Migraine: A Canada-Wide Cross-Sectional Study

Hiten Naik<sup>1,2</sup> , Alexander C.T. Tam<sup>3</sup>, Logan Trenaman<sup>4</sup>, Larry Lynd<sup>2,3</sup> and Wei Zhang<sup>2,3</sup>

<sup>1</sup>Department of Medicine, The University of British Columbia, Vancouver, BC, Canada, <sup>2</sup>Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada, <sup>3</sup>Centre for Advancing Health Outcomes, Providence Research, Vancouver, BC, Canada and <sup>4</sup>Department of Health Systems and Population Health, School of Public Health, University of Washington, Seattle, WA, USA

**ABSTRACT: Background:** Migraine can affect adults during their most productive years, yet few studies in Canada have examined the relationship between migraine-related disability and productivity loss. In particular, the impact of migraine on unpaid productivity loss has not been quantified. **Methods:** In this cross-sectional study, employed adults living with migraine were recruited from across Canada to complete a web-based questionnaire. Migraine-related disability was assessed using the Migraine Disability Assessment questionnaire, and productivity loss was evaluated using the Valuation of Lost Productivity questionnaire. Multiple regression models were used to quantify the association between migraine-related disability level and productivity loss after adjusting for relevant clinical, occupational and sociodemographic covariates. **Results:** There were 441 participants, of which 60.1% were female, and the mean (SD) age was 37.7 (10.9). Compared to participants with little to no migraine-related disability, hours of total productivity loss were higher among those with moderate disability (54.1 [95% CI: 10.2–98.1] adjusted hours per 3 months) and severe disability (110.5 [95% CI: 65.5–155.6] adjusted hours per 3 months); paid productivity loss was higher among participants with moderate disability (32.4 [95% CI: 3.1–61.8] adjusted hours per 3 months) and severe disability (61.6 [95% CI: 31.5–91.7] adjusted hours per 3 months); and unpaid productivity loss was greater in those with severe disability (43.5 [95% CI: 12.7–74.3] adjusted hours per 3 months). **Conclusions:** Greater migraine-related disability was associated with more total, paid and unpaid productivity loss among employed adults. These data will be valuable when evaluating the cost-effectiveness of emerging migraine therapies.

**RÉSUMÉ: Pertes de productivité associées à l'invalidité attribuable à la migraine: une étude transversale à l'échelle du Canada. Contexte:** La migraine peut toucher les adultes pendant leurs années les plus productives, mais peu d'études au Canada se sont penchées sur la relation entre l'invalidité liée à la migraine et la perte de productivité. En particulier, l'impact de la migraine sur les pertes de productivité non rémunérée n'a pas encore été quantifié. **Méthodes:** Dans cette étude transversale, des adultes souffrant de migraine ayant un emploi ont été recrutés dans tout le Canada pour remplir un questionnaire en ligne. L'invalidité liée à la migraine a été évaluée à l'aide du questionnaire *Migraine Disability Assessment* (ou MIDAS) tandis que les pertes de productivité, elles, ont été évaluées à l'aide du questionnaire *Valuation of Lost Productivity* (VOLP). Des modèles de régression multiple ont été utilisés pour quantifier l'association entre le niveau d'invalidité lié à la migraine et les pertes de productivité, et ce, après ajustement des covariables cliniques, professionnelles et sociodémographiques pertinentes. **Résultats:** Au total, 441 individus ont participé à cette étude, dont 60,1 % étaient des femmes; leur âge moyen (écart-type) était de 37,7 (10,9). Par rapport aux participants ayant peu ou pas d'invalidité liée à la migraine, les heures de perte de productivité totale étaient plus élevées chez ceux donnant à voir une invalidité modérée (54,1 [IC 95 % : 10,2–98,1] heures ajustées par 3 mois) et une invalidité sévère (110,5 [IC 95 % : 65,5–155,6] heures ajustées par 3 mois). Les pertes de productivité rémunérée étaient plus élevées chez les participants faisant les frais d'une invalidité modérée (32,4 [IC 95 % : 3,1–61,8] heures ajustées par 3 mois) et une invalidité sévère (61,6 [IC 95 % : 31,5–91,7] heures ajustées par 3 mois). Enfin, les pertes de productivité non rémunérée étaient plus élevées chez les participants aux prises avec une invalidité sévère (43,5 [IC 95 % : 12,7–74,3] heures ajustées par 3 mois). **Conclusions:** Une plus grande invalidité liée à la migraine a été associée à de plus grandes pertes totales de productivité, qu'elle soit rémunérée ou non, chez des adultes ayant un emploi. Ces données seront précieuses pour évaluer le rapport coût-efficacité des nouvelles thérapies contre la migraine.

**Keywords:** Migraine disorders; headache; health economics; patient-reported outcomes; work capacity evaluation; employment; disability leave; sick days; cross-sectional study

(Received 28 June 2024; final revisions submitted 20 October 2024; date of acceptance 26 October 2024)

**Corresponding author:** Wei Zhang; Email: [wzhang@advancinghealth.ubc.ca](mailto:wzhang@advancinghealth.ubc.ca)

**Cite this article:** Naik H, Tam ACT, Trenaman L, Lynd L, and Zhang W. Productivity Loss Associated with Disability from Migraine: A Canada-Wide Cross-Sectional Study. *The Canadian Journal of Neurological Sciences*, <https://doi.org/10.1017/cjn.2024.337>

© The Author(s), 2024. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.

### Highlights

- Few studies in Canada have examined the relationship between migraine-related disability and productivity loss.
- In this cross-sectional study, employed adults living with migraine across Canada completed the Valuation of Lost Productivity questionnaire.
- After adjusting for relevant covariates, greater migraine-related disability was associated with more total, paid and unpaid productivity loss.

## Introduction

Migraine poses a significant socioeconomic burden on society. It is estimated that over 1 billion people are affected by migraine worldwide,<sup>1</sup> and of all medical conditions, migraine is responsible for the second-greatest number of years lived with disability.<sup>2</sup> Migraine impairs quality of life and has been linked to several chronic conditions, including insomnia, depression, anxiety and gastric ulcers.<sup>3</sup> The direct healthcare costs related to health resource utilization and treatment of migraine are significant.<sup>4–6</sup>

In economic evaluations, the indirect costs related to work productivity loss are also an important consideration, given that migraine disproportionately impacts working-age adults.<sup>7–9</sup> Multiple studies have shown that the productivity loss associated with migraine is substantial.<sup>9–17</sup> However, additional research is needed for several reasons. First, there is a paucity of observational studies in North America that have captured data examining the impact of migraine on presenteeism (reduced productivity while at work), which may be a greater contributor to migraine-related productivity loss than absenteeism.<sup>15,16,18,19</sup> Second, studies have not estimated productivity loss related to unpaid work (such as childcare and housework), which is an important consideration given that migraine is more common in women.<sup>7,8,20,21</sup> Third, the productivity loss associated with different categories of migraine-related disability or severity is rarely evaluated.<sup>15,17–19</sup> Fourth, most studies assessing productivity loss from migraine have used the Work Productivity and Activity Impairment (WPAI) questionnaire, which quantifies productivity losses as a percent impairment.<sup>6,15,19,22–27</sup> Estimating productivity loss in hours would provide a more direct quantification of the cost burden.<sup>28</sup>

Further comprehensive and patient-centered valuations of productivity loss from migraine would be valuable for assessing the economic impact of this condition, particularly when considering the perspective of the employer and society. These data could also be used in cost-effectiveness analyses as new migraine therapies reach the market. Accordingly, we conducted a cross-sectional study that examined productivity loss among individuals with migraine across Canada. The study's primary objective was to examine the association between different levels of migraine-related disability and productivity loss.

## Methods

### Study design and participants

This was a cross-sectional study in which participants completed an online questionnaire. Participants were recruited from throughout Canada from an Ipsos market research panel. Potentially eligible members from the Ipsos iSay rewards community were invited to participate via the Ipsos iSay website, the mobile app and/or text message (depending on the member's preferences). To be eligible, participants were required to be 19 or older, employed, a resident of Canada, have a history of migraine

and be able to comprehend English or French. The questionnaire was administered electronically by Qualtrics (Provo, Utah). Participants completed eligibility screening questions through the Ipsos iSay platform before electronically accessing the main study questionnaire. Through the eligibility screening, participants were considered to have a history of migraine if they reported being previously diagnosed by a clinician. We targeted 450 total participants for this study and set Qualtrics quotas to ensure an approximately equal distribution of respondents for different levels of migraine-related disability. Some participants were prevented from completing the questionnaire if their responses deemed them ineligible (e.g., unemployed) or the predetermined quota had already been met.

This study was designed and executed in collaboration with a patient partner living with migraine and two additional patient partners with chronic disease (one living with atopic dermatitis and one with alopecia areata). A draft of the questionnaire was piloted in three people with a history of migraine, three people with atopic dermatitis and one person with alopecia areata. Questions related to productivity loss and demographics were the same for the three diseases. The questions related to disease history, severity and treatment were disease-specific. After they completed the draft questionnaire, participants were interviewed for feedback, and appropriate revisions were made. The final questionnaire was available to study participants in English and French. Based on feedback from our patient partner, it was presented in dark mode to reduce possible migraine exacerbation from photophobia.<sup>29–31</sup>

This study was approved by the University of British Columbia Research Ethics Board (REB # H22-03211). Recruitment for this study occurred between December 4, 2023, and February 12, 2024. Participants provided electronic consent before starting the questionnaire. We followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for reporting observational studies.<sup>32</sup>

### Migraine-related disability

Migraine-related disability was assessed using the Migraine Disability Assessment (MIDAS) questionnaire.<sup>33</sup> The first five items of the MIDAS ask about the number of days in the past 3 months that were affected by migraine: the number of missed work or school days; missed household chores days; missed non-work activity days; days at work or school where productivity was reduced by half or more; and days in which household work was reduced by half or more.<sup>33</sup> The total MIDAS score was derived by summing the total number of days affected by migraine.<sup>33</sup> Using previously established cutoffs, we categorized participants as having little to no disability (MIDAS score 0–5), mild disability (MIDAS score 6–10), moderate disability (MIDAS score 11–20) or severe disability (MIDAS score  $\geq 21$ ).<sup>33</sup>

The MIDAS questionnaire has two additional items. The sixth item asks about the number of days the participant has experienced headaches over the past 3 months, and the seventh item asks about the average severity of the headaches (on a scale of 0–10). These two items were used in sensitivity analyses.

### Outcomes

Productivity loss was measured using the Valuation of Lost Productivity (VOLP) questionnaire.<sup>34</sup> The VOLP consists of questions about health-related paid and unpaid productivity loss. The questions about productivity loss refer to health in general and are not migraine-specific. Paid productivity loss comprises

absenteeism (number of absent workdays due to health) and presenteeism (hours actually taken to complete all work relative to the hours taken to complete the same work if not experiencing any health problems). Unpaid work loss represents the hours of paid and unpaid help received for unpaid work activities (such as childcare and housework) due to health.<sup>34</sup> It has been validated and used in other chronic conditions to estimate health-related productivity loss in hours over the preceding 3 months.<sup>34–38</sup> In this study, the primary outcome was total hours of productivity loss, calculated as the sum of paid productivity loss (from absenteeism and presenteeism) and unpaid productivity loss. The hours of total paid productivity loss, hours lost due to absenteeism, hours lost due to presenteeism and hours of unpaid productivity loss were evaluated as secondary outcomes. Details regarding calculating the productivity loss outcomes using the VOLP are described in the supplemental methods.

An additional secondary outcome was the percent overall work impairment and percent activity impairment due to health as measured by the WPAI – General Health questionnaire. The WPAI is a validated measure that assesses the impact of health on work productivity and impairment of regular activities in the prior week.<sup>22,39,40</sup> Calculations for work and activity impairment using the WPAI are outlined in the supplemental methods.

### Statistical analysis

Mean values for each outcome were calculated for different levels of migraine-related disability based on MIDAS responses.<sup>33</sup> We then used ordinary least squares (OLS) regressions to measure the association between migraine-related disability levels and the outcomes while adjusting for potential confounding variables. These additional covariates were prespecified based on a review of the literature and were captured from questionnaire responses.<sup>8,11,35,37,41</sup> These included age, gender, ethnicity, marital status, education level, work income, household income, employment status (part of VOLP), work habits and number of comorbidities. We chose to use OLS models for productivity loss outcomes based on previously published practical recommendations for regression model selection in productivity loss analyses.<sup>42</sup>

We conducted sensitivity analyses based on responses to the two additional MIDAS items to determine if outcomes were associated with (1) the number of days with migraine over the past 3 months and (2) the average severity of migraine.

Statistical tests were two-sided, and the threshold for significance was  $p < 0.05$ . Analyses were performed using R statistical software version 4.3.3 and Stata version 15.1 (StataCorp LLC, College Station, TX).

### Results

In total, 441 participants were included in the analyses. Due to incomplete or invalid responses, 10 participants were excluded from the VOLP analyses, and 17 were excluded from the WPAI analyses.

Characteristics of the study population are described in Table 1. The mean (SD) age was 37.7 (10.9); 60.1% were women, 75.5% were White, 81.6% worked full-time and 50.1% were sedentary at work. Of note, the no to little migraine-related disability level group had the greatest proportion of participants at the highest work income level (43.1% with over \$100,000), and the severe migraine-related disability level group had the greatest proportion (45.5%) of participants with two or more comorbidities.

The migraine preventative strategies, treatments and workplace accommodations reported by participants are reported in Table S1.

The most commonly used strategies by participants to prevent migraine were lifestyle changes (73.0%) and oral medications (68.7%); the most common migraine treatment was oral medications (87.3%). Concerning workplace accommodations for health conditions, 38.1% reported being granted paid leave, and 28.8% had been granted flexible work arrangements.

The mean (SD) hours of total productivity loss in the past 3 months were higher at greater levels of migraine-related disability (61.0 [120.4] hours per 3 months for little to no disability, 105.9 [128.7] for mild disability, 132.3 [148.8] for moderate and 196.5 [214.5] for severe) (Table 2). Specifically, paid productivity loss (including absenteeism and presenteeism) increased with migraine-related disability level (47.6 [106.4], 64.8 [99.1], 85.0 [96.3] and 119.8 [109.4], hours per 3 months, respectively) and so did the mean (SD) hours of unpaid productivity loss (16.5 [61.0], 40.4 [89.5], 46.8 [97.6] and 76.0 [166.9] hours per 3 months, respectively). The mean (SD) hours of absenteeism increased greatly with migraine-related disability levels (7.0 [13.4], 13.9 [16.2], 29.4 [48.2] and 50.9 [56.2] hours per 3 months, respectively). However, the increase in mean (SD) hours of presenteeism across disability levels was not as pronounced (40.4 [102.1], 50.8 [96.1], 55.5 [84.0] and 68.7 [88.5] hours per 3 months, respectively), and for all levels, presenteeism contributed more to paid productivity loss than absenteeism.

The mean (SD) WPAI percent overall work impairment in the prior 7 days reported by participants also increased with migraine-related disability level (23.1 [22.4]% for little to no disability, 37.9 [26.2]% for mild disability, 49.5 [26.5]% for moderate and 65.4 [22.4]% for severe disability), as did percent activity impairment (23.2 [22.2]%, 35.9 [23.9]%, 46.7 [23.0]% and 58.5 [22.1]%, respectively).

In our multiple regression models, moderate migraine-related disability was also associated with greater total and paid productivity loss compared with little to no disability (54.1 [10.2, 98.1] adjusted hours,  $p < 0.05$ ; 32.4 [3.1, 61.8] adjusted hours,  $p < 0.05$ , respectively) (Table 3; Table S2). Furthermore, having severe migraine-related disability was associated with greater total productivity loss (110.5 [65.5, 155.6] adjusted hours,  $p < 0.001$ ), paid productivity loss (61.6 [31.5, 91.7] adjusted hours,  $p < 0.001$ ) and unpaid productivity loss (43.5 [12.7, 74.3] adjusted hours,  $p < 0.01$ ) compared with little to no disability. Similarly, in models evaluating overall work impairment derived from WPAI responses, greater levels of migraine-related disability were associated with greater percent impairment (13.1% [6.2, 20.0],  $p < 0.001$  for mild; 23.0% [16.3, 29.8],  $p < 0.001$  for moderate; and 37.3% [30.3, 44.2],  $p < 0.001$  for severe disability compared with little to no disability) (Table S3).

In sensitivity analyses, more headache days over the past 3 months and greater average migraine severity were associated with greater total productivity loss, paid productivity loss, unpaid productivity loss, overall work impairment and activity impairment (Table S4).

### Discussion

In this cross-sectional study involving participants from across Canada, we compared productivity loss between individuals with different levels of migraine-related disability. We found that components of paid and unpaid productivity loss (as measured by VOLP), as well as work and activity impairment (as measured by WPAI), were higher in individuals with more disability from migraine.

This is one of the first observational studies to examine productivity loss among people with migraine in a Canadian

**Table 1.** Characteristics of the study population

Characteristic	Migraine-related disability level				All N (%)
	Little to no (MIDAS 0–5) N (%)	Mild (MIDAS 6–10) N (%)	Moderate (MIDAS 11–20) N (%)	Severe (MIDAS ≥21) N (%)	
<b>Total, row %</b>	109 (24.7)	111 (25.2)	111 (25.2)	110 (24.9)	441 (100)
<b>Questionnaire language</b>					
English	96 (88.1)	101 (91.0)	103 (92.8)	102 (92.7)	402 (91.2)
French	13 (11.9)	10 (9.0)	8 (7.2)	8 (7.3)	39 (8.8)
<b>Gender<sup>a</sup></b>					
Man	65 (59.6)	42 (37.8)	38 (34.2)	31 (28.2)	176 (39.9)
Woman	44 (40.4)	69 (62.2)	73 (65.8)	79 (71.8)	265 (60.1)
<b>Age, mean (SD)</b>	36.6 (12.7)	38.8 (10.1)	38.2 (9.5)	37.3 (11.0)	37.7 (10.9)
<b>Province or region</b>					
Alberta	40 (36.7)	21 (18.9)	25 (22.5)	22 (20.0)	108 (24.5)
Atlantic Canada <sup>b</sup>	≤5 (≤4.6)	10 (9.0)	13 (11.7)	≤5 (≤4.5)	30 (6.8)
British Columbia	≤5 (≤4.6)	8 (7.2)	15 (13.5)	10 (9.1)	37 (8.4)
Manitoba	≤5 (≤4.6)	≤5 (≤4.5)	≤5 (≤4.5)	≤5 (≤4.5)	7 (1.6)
Ontario	30 (27.5)	43 (38.7)	36 (32.4)	53 (48.2)	162 (36.7)
Quebec	29 (26.6)	21 (18.9)	16 (14.4)	15 (13.6)	81 (18.4)
Saskatchewan	≤5 (≤4.6)	8 (7.2)	≤5 (≤4.5)	≤5 (≤4.5)	14 (3.2)
Territories <sup>c</sup>	≤5 (≤4.6)	≤5 (≤4.5)	≤5 (≤4.5)	≤5 (≤4.5)	≤5 (≤4.5)
<b>Race/ethnicity</b>					
Other race/ethnicity <sup>d</sup>	23 (23.1)	20 (18.0)	26 (23.4)	39 (35.5)	108 (24.5)
White	86 (78.9)	91 (82.0)	85 (76.6)	71 (64.5)	333 (75.5)
<b>Marital status</b>					
Not married or common-law	66 (60.6)	35 (31.5)	38 (34.2)	49 (44.5)	188 (42.6)
Married or common-law	43 (39.4)	76 (68.5)	73 (65.8)	61 (55.5)	253 (57.4)
<b>Education</b>					
No university or college education	63 (57.8)	55 (49.5)	66 (59.5)	64 (58.2)	248 (56.2)
University or college education	46 (42.2)	56 (50.5)	45 (40.5)	46 (41.8)	193 (43.8)
<b>Work income</b>					
<\$50,000	31 (28.4)	28 (25.2)	28 (25.2)	33 (30.0)	120 (27.2)
\$50,000–\$99,999	31 (28.4)	52 (46.8)	39 (35.1)	49 (44.5)	171 (38.8)
≥\$100,000	47 (43.1)	31 (27.9)	44 (39.6)	28 (25.5)	150 (34.0)
<b>Household income</b>					
<\$50,000	16 (14.7)	16 (14.4)	20 (18.0)	24 (21.8)	76 (17.2)
\$50,000–\$99,999	17 (15.6)	27 (24.3)	23 (20.7)	37 (33.6)	104 (23.6)
\$100,000–\$149,999	36 (33.0)	40 (36.0)	35 (31.5)	28 (25.5)	139 (31.5)
≥\$150,000	40 (36.7)	28 (25.2)	33 (29.7)	21 (19.1)	122 (27.7)
<b>Number of comorbidities<sup>e</sup></b>					
0	57 (52.3)	36 (32.4)	33 (29.7)	31 (28.2)	157 (35.6)
1	35 (32.1)	47 (42.3)	45 (40.5)	29 (26.4)	156 (35.4)
≥2	17 (15.6)	28 (25.2)	33 (29.7)	50 (45.5)	128 (29.0)
<b>Employment status</b>					
Working full-time	93 (85.3)	93 (83.8)	94 (84.7)	80 (72.7)	360 (81.6)
Working part-time, self-employed or other	16 (14.7)	18 (16.2)	17 (15.3)	30 (27.3)	81 (18.4)
<b>Workdays per week, mean (SD)</b>	4.8 (0.9)	4.8 (1.0)	4.9 (0.7)	4.8 (0.9)	4.8 (0.9)

(Continued)



**Table 1.** Characteristics of the study population (Continued)

Characteristic	Migraine-related disability level				All N (%)
	Little to no (MIDAS 0–5) N (%)	Mild (MIDAS 6–10) N (%)	Moderate (MIDAS 11–20) N (%)	Severe (MIDAS ≥21) N (%)	
Work hours per week, mean (SD)	33.0 (13.1)	34.9 (11.8)	33.7(12.6)	33.3 (14.2)	33.7 (12.9)
<b>Work habits</b>					
Sedentary at work	56 (51.4)	55 (49.5)	62 (55.9)	48 (43.6)	221 (50.1)
Mildly active at work	41 (37.6)	43 (38.7)	35 (31.5)	46 (41.8)	165 (37.4)
Moderate to strenuous activity at work	12 (11.0)	13 (11.7)	14 (12.6)	16 (14.5)	55 (12.5)
<b>Work from home</b>					
No work from home	44 (40.4)	36 (32.4)	39 (35.1)	44 (40.0)	163 (37.0)
Work from home at least part of the time	65 (59.6)	75 (67.6)	72 (64.9)	66 (60.0)	278 (63.0)

All percentages represent column proportions unless otherwise indicated.

MIDAS = Migraine Disability Assessment; SD = standard deviation.

<sup>a</sup>“Non-binary person” was an option provided for gender, but no participants selected this.

<sup>b</sup>Atlantic Canada includes the provinces Nova Scotia, New Brunswick, Prince Edward Island and Newfoundland and Labrador.

<sup>c</sup>Territories include Yukon, Northwest Territories and Nunavut.

<sup>d</sup>Other race/ethnicity includes South Asian (e.g., East Indian, Pakistani, Sri Lankan, etc.), Chinese, First Nations, Southeast Asian (e.g., Vietnamese, Cambodian, Malaysian, Laotian, etc.), West Asian, Filipino, Latin American, Métis, Korean, Japanese, Arab, Inuit, Black, Indigenous/Aboriginal (not included elsewhere), Other and mixed (i.e., more than one) ethnicities.

<sup>e</sup>Comorbidities include asthma, arthritis or osteoporosis, back problems, cancer, cardiovascular disease, chronic obstructive pulmonary disease, diabetes, mental health conditions, neurologic conditions, digestive diseases, fibromyalgia or chronic fatigue syndrome, kidney disease, liver disease or gallbladder problems.

**Table 2.** Productivity loss and percentage impairment by migraine-related disability level

Outcomes	Migraine-related disability level				All N = 441
	Little to no (MIDAS 0–5) Mean (SD) N = 109	Mild (MIDAS 6–10) Mean (SD) N = 111	Moderate (MIDAS 11–20) Mean (SD) N = 111	Severe (MIDAS ≥20) Mean (SD) N = 110	
<b>VOLP (last 3 months)</b>					
Total work productivity loss hours <sup>†</sup>	61.0 (120.4)	105.9 (128.7)	132.3 (148.8)	196.5 (214.5)	124.8 (164.8)
Paid work productivity loss hours <sup>†</sup>	47.6 (106.4)	64.8 (99.1)	85.0 (96.3)	119.8 (109.4)	79.8 (106.0)
Absenteeism loss hours	7.0 (13.4)	13.9 (16.2)	29.4 (48.2)	50.9 (56.2)	25.3 (41.9)
Presenteeism loss hours <sup>†</sup>	40.4 (102.1)	50.8 (96.1)	55.5 (84.0)	68.7 (88.5)	54.1 (93.0)
Unpaid work productivity loss hours	16.5 (61.0)	40.4 (89.5)	46.8 (97.6)	76.0 (166.9)	45.0 (112.4)
<b>WPAI (last 7 days)</b>					
Percent overall work impairment*	23.1 (22.4)	37.9 (26.2)	49.5 (26.5)	65.4 (22.4)	44.1 (28.9)
Percent activity impairment	23.2 (22.2)	35.9 (23.9)	46.7 (23.0)	58.5 (22.1)	41.1 (26.2)

MIDAS = Migraine Disability Assessment; SD = standard deviation; VOLP = Valuation of Lost Productivity; WPAI = Work Productivity and Activity Impairment.

<sup>†</sup>Sample size N = 431 and 10 participants did not provide valid answers for questions related to presenteeism.

\*Sample size for the WPAI percent work impairment outcome N = 424 and 17 participants had valid question skip patterns (not currently employed (working for pay) or 0 hours missed because of health problems and 0 hours worked in the past 7 days).

context. As part of their study on the overall economic burden of migraine, Amoozegar et al. estimated the percentage of patients who had productivity loss after administering the WPAI questionnaire to 287 patients with migraine.<sup>16</sup> Our study builds on this work by including a larger cohort, estimating productivity loss in hours, measuring unpaid losses and stratifying by migraine-related disability.

Our findings also contribute to accumulating evidence that migraine-related disability has a significant impact on work productivity loss.<sup>15,18,43</sup> For example, a recent study by Wong et al.

evaluated WPAI outcomes by MIDAS level in employees within the banking sector in Malaysia.<sup>15</sup> Compared to this study, we observed that the percent overall work impairment and activity impairment for little to no, mild and moderate disability levels were lower, but we observed greater impairment for severe disability. Similar to our study, this Malaysian study also reported significant levels of productivity loss associated with just minimal levels of migraine-related disability.<sup>15</sup> Based on VOLP responses, individuals in our study with little to no migraine-related disability had an average of 61 hours of productivity loss over the prior 3

**Table 3.** Multiple regression models for productivity loss and percentage impairment by migraine-related disability level

Outcomes	Migraine-related disability level			
	Little to no (MIDAS 0–5)	Mild (MIDAS 6–10) Coefficient (95% CI)	Moderate (MIDAS 11–20) Coefficient (95% CI)	Severe (MIDAS ≥21) Coefficient (95% CI)
<b>VOLP (last 3 months)</b>				
Total productivity loss hours	[Reference]	37.4 (–6.5, 81.4)	54.1 (10.2, 98.1)*	110.5 (65.5, 155.6)***
Paid productivity loss hours	[Reference]	16.8 (–12.5, 46.1)	32.4 (3.1, 61.8)*	61.6 (31.5, 91.7)***
Unpaid productivity loss hours	[Reference]	15.6 (–14.2, 45.5)	17.3 (–12.7, 47.2)	43.5 (12.7, 74.3)**
<b>WPAI (last 7 days)</b>				
Percent overall work impairment	[Reference]	13.1 (6.2, 20.0)***	23.0 (16.3, 29.8)***	37.3 (30.3, 44.2)***
Percent activity impairment	[Reference]	11.7 (5.4, 17.9)***	20.9 (14.7, 27.2)***	31.2 (24.7, 37.7)***

Models are adjusted for gender, age, ethnicity, marital status, education, household income, employment status, work habits and the number of comorbidities reported. Complete models are reported in Table S2 and Table S3. MIDAS = Migraine Disability Assessment; WPAI = Work Productivity and Activity Impairment; VOLP = Valuation of Lost Productivity.

\* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ .

months. This finding is an indication that even mild or treated migraine disorder may result in significant occupational impairment.

Like the Malaysian study, our results showed that presenteeism (productivity loss at work) is significant among persons with migraine. Regardless of migraine-related disability level, presenteeism contributed more to paid productivity loss than absenteeism. This is a relevant finding from the employer's perspective, as individuals with migraine have experienced stigma, and there is potential for migraine exacerbation in the workplace.<sup>18,44–48</sup> Indeed, employers have become increasingly aware of the importance of developing work environments and programs that support people with migraine.<sup>48–50</sup> Studies have suggested that reducing screen time, implementing migraine-specific disease management programs, safe/ dark rooms and referrals to occupational health could be beneficial for people with migraine.<sup>18,50</sup> However, further research is needed to evaluate whether these interventions can reduce productivity loss.<sup>48,50</sup>

Our study also observed that unpaid work significantly contributes to productivity loss in people with migraine. Unpaid work, such as caregiving, can affect mental health, impair health-related quality of life and have significant societal value.<sup>51,52</sup> However, unpaid losses are not routinely considered in economic analyses and have not been accounted for in migraine productivity loss assessments until our study. Women are estimated to spend 2–10 times more time on unpaid work activities than men.<sup>53</sup> In the context of migraine – which is at least twice as prevalent in women – it is imperative to consider unpaid losses when examining the economic benefits of an intervention.<sup>7,8,54</sup>

The results of this study highlight the economic value of developing effective migraine treatments. For example, recent randomized trials showed that 3 months of treatment with the calcitonin-gene-related peptide (CGRP) antagonist galcanezumab resulted in MIDAS score improvements of over 20 points.<sup>55,56</sup> This level of improvement is enough to reduce migraine-related disability from severe to little or no symptoms; based on our data, this would represent an adjusted total productivity loss improvement of 110.5 hours in 3 months and an adjusted paid productivity loss improvement of 61.6 hours (i.e., nearly two full workweeks).

The productivity loss valuations reported in this study could be applied to future cost-effectiveness analyses. Over two decades ago,

productivity loss valuations played a role in demonstrating the efficacy of triptans;<sup>57–59</sup> similar assessments will be required for CGRP receptor antagonists and other new migraine therapies.<sup>60</sup> While recent cost-effectiveness analyses of CGRP receptor antagonists have used WPAI outcome data,<sup>50,52</sup> the VOLP should be considered as it was designed for use in economic evaluations or cost of illness studies and provides a more comprehensive assessment from a societal perspective.<sup>28</sup> Unlike WPAI, the VOLP estimates paid and unpaid work productivity loss in terms of time, which can then be valued in monetary terms.<sup>28</sup>

However, it is prudent to consider the limitations of our study. As it was a cross-sectional analysis, causal relationships between migraine-related disability levels and the outcomes cannot be established. Since we relied on online convenience sampling of participants and set quotas to ensure a similar number of participants for each disability level group, the study population should not be taken to represent all employed Canadian residents with migraine. In addition, VOLP and WPAI captured productivity loss due to health (any physical, mental or emotional problems or symptoms) as opposed to migraine-specific productivity loss. The VOLP was developed as a generic health instead of a disease-specific questionnaire because patients may have difficulty attributing their sick leaves or reduced work productivity to a specific disease, especially when they have multiple chronic health conditions, and because they are less likely to attribute the related treatment side effects or comorbidities to a specific disease.<sup>28,61</sup> The severe disability group was more likely to have at least two comorbidities and thus tended to have higher health-related productivity loss. Thus, the findings on the adjusted differences between different disability levels have more practical implications than the outcomes for a given disability level. Furthermore, we relied solely on self-report (as opposed to clinical records) to ascertain migraine diagnosis, which may have led to the inclusion of individuals who did not truly have a migraine disorder. Similarly, comorbidity information was captured from questionnaire responses and was not comprehensive; this may have resulted in unmeasured confounding.

Our study has several strengths. We captured data in two languages from regions across Canada and included participants from various socioeconomic backgrounds and workplaces. In contrast to previous productivity loss assessments of migraine in Canada, our study included a larger sample size, and recruitment

was not limited to specific clinics or patients with particular treatment profiles.<sup>16</sup> The diversity of our study population increases the generalizability of our findings – an important consideration given that productivity loss from migraine has been shown to differ by occupation and region.<sup>12</sup> Furthermore, all our study outcomes were patient-reported, and we applied a patient-oriented approach by engaging patient partners, which helped ensure that the procedures and results were centered on the values of individuals with migraine and other chronic diseases. Lastly, a major strength of our study was the selection of the outcome measures. Although the VOLP has not been previously applied to individuals with migraine, it has been used for several other diseases and permitted a comprehensive valuation of productivity loss, including paid and unpaid losses.<sup>34,37,38</sup> This was complemented by including the WPAI outcomes, allowing comparisons with other studies.<sup>6,15,19,22,24–27,62</sup>

## Conclusion

In conclusion, greater migraine-related disability was associated with greater total, paid and unpaid productivity loss among employed adults. These findings demonstrate the economic impact of migraine and highlight the potential societal value of effective interventions.

**Supplementary material.** The supplementary material for this article can be found at <https://doi.org/10.1017/cjn.2024.337>.

**Acknowledgments.** The authors would like to thank Ms. Amanda Brar for her insights as a patient partner during the development of this study. Dr Naik would like to acknowledge the support of the University of British Columbia Clinician Investigator Program and a CAN-TAP-TALENT and Michael Smith Health Research BC Postdoctoral Fellowship. Dr Trenaman would like to acknowledge the support of the Leo Greenawalt Endowed Professorship in Health Policy. Dr Zhang would like to acknowledge the support of the Michael Smith Health Research BC Scholar Award.

**Author contributions.** LT, LL and WZ conceived the study. HN, AT and WZ were involved in data acquisition. AT conducted the statistical analysis. All authors were involved in data interpretation. HN wrote the first draft of the manuscript. All authors were involved in critically reviewing the manuscript for important intellectual content. All authors approved of the final manuscript.

**Funding statement.** This study was supported by a grant-in-aid from Pfizer Canada.

The funders had no role in the design and conduct of the study, data collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication.

**Competing interests.** None.

**Ethical approval.** The University of British Columbia Research Ethics Board (REB # H22-03211) approved this study. All participants provided electronic consent.

**Availability of data and materials.** The datasets used and/or analyzed during the present study are available from the corresponding author upon reasonable request.

## References

1. Safiri S, Pourfathi H, Eagan A, et al. Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. *Pain*. 2022;163:E293–E309.
2. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Disease and injury incidence and prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the global burden of disease study 2016. *Lancet*. 2017;390:1211–59.
3. Buse DC, Reed ML, Fanning KM, et al. Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study. *J Headache Pain*. 2020;21:23. DOI: [10.1186/s10194-020-1084-y](https://doi.org/10.1186/s10194-020-1084-y).
4. Gilligan AM, Foster SA, Sainski-Nguyen A, et al. Direct and indirect costs among United States commercially insured employees with migraine. *J Occup Environ Med*. 2018;60:1120–7.
5. Ford JH, Ye W, Nichols RM, et al. Treatment patterns and predictors of costs among patients with migraine: evidence from the United States medical expenditure panel survey. *J Med Econ*. 2019;22:849–58.
6. Garcia-Azorin D, Moya-Alarcón C, Armada B, et al. Societal and economic burden of migraine in Spain: results from the 2020 National health and wellness survey. *J Headache Pain*. 2024;25:38.
7. Schramm SH, Obermann M, Katsarava Z, et al. Epidemiological profiles of patients with chronic migraine and chronic tension-type headache. *J Headache Pain*. 2013;14:1–8.
8. Amiri P, Kazeminasab S, Nejadghaderi SA, et al. Migraine: a review on its history, global epidemiology, risk factors, and comorbidities. *Front Neurol*. 2022;12:1–15. DOI: [10.3389/fneur.2021.800605](https://doi.org/10.3389/fneur.2021.800605).
9. Seddik AH, Branner JC, Ostwald DA, et al. The socioeconomic burden of migraine: An evaluation of productivity losses due to migraine headaches based on a population study in Germany. *Cephalalgia*. 2020;40:1551–60.
10. Allen D, Hines EW, Pazdernik V, et al. Four-year review of presenteeism data among employees of a large United States health care system: a retrospective prevalence study. *Hum Resour Health*. 2018;16:1–10. DOI: [10.1186/s12960-018-0321-9](https://doi.org/10.1186/s12960-018-0321-9).
11. Landy SH, Runken MC, Bell CF, et al. Assessing the impact of migraine onset on work productivity. *J Occup Environ Med*. 2011;53:74–81.
12. Rondinella S, Silipo DB. The effects of chronic migraine on labour productivity: evidence from Italy. *Labour*. 2023;37:1–32.
13. Alkahtani RF, Alrumaih SS, Algezlan SS, et al. The impact of migraine disease on work productivity and quality of life among the adults in Riyadh, Saudi Arabia. *Cureus*. 2022;14:1–13. DOI: [10.7759/cureus.27733](https://doi.org/10.7759/cureus.27733).
14. Husoy A, Katsarava Z, Steiner TJ. The relationship between headache-attributed disability and lost productivity: 3 attack frequency is the dominating variable. *J Headache Pain*. 2023;24:7 DOI: [10.1186/s10194-023-01546-9](https://doi.org/10.1186/s10194-023-01546-9).
15. Wong LP, Alias H, Bhoo-Pathy N, et al. Impact of migraine on workplace productivity and monetary loss: a study of employees in banking sector in Malaysia. *J Headache Pain*. 2020;21:68. DOI: [10.1186/s10194-020-01144-z](https://doi.org/10.1186/s10194-020-01144-z).
16. Amoozegar F, Khan Z, Oviedo-Ovando M, et al. The burden of illness of migraine in Canada: new insights on humanistic and economic cost. *Can J Neurol Sci*. 2022;49:249–62.
17. Kim Y, Han S, Suh HS. The impact of migraine and probable migraine on productivity loss in Korea: a cross-sectional online survey. *PLoS One*. 2022;17. DOI: [10.1371/journal.pone.0277905](https://doi.org/10.1371/journal.pone.0277905).
18. Haw NJ, Cabaluna IT, Kaw GE, et al. A cross-sectional study on the burden and impact of migraine on work productivity and quality of life in selected workplaces in the Philippines. *J Headache Pain*. 2020;21:125. DOI: [10.1186/s10194-020-01191-6](https://doi.org/10.1186/s10194-020-01191-6).
19. Ishii R, Schwedt TJ, Dumkrieger G, et al. Chronic versus episodic migraine: the 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. *Headache*. 2021;61:992–1003.
20. Graves EB, Gerber BR, Berrigan PS, et al. Epidemiology and treatment utilization for Canadian patients with migraine: a literature review. *J Int Med Res*. 2022;50:1–22. DOI: [10.1177/03000605221126380](https://doi.org/10.1177/03000605221126380).
21. Delaruelle Z, Ivanova TA, Khan S, et al. Male and female sex hormones in primary headaches. *J Headache Pain*. 2018;19:1–12. DOI: [10.1186/s10194-018-0922-7](https://doi.org/10.1186/s10194-018-0922-7).

22. Ford JH, Ye W, Ayer DW, et al. Validation and meaningful within-patient change in work productivity and activity impairment questionnaire (WPAI) for episodic or chronic migraine. *J Patient Rep Outcomes*. 2023;7:34. DOI: [10.1186/s41687-023-00552-4](https://doi.org/10.1186/s41687-023-00552-4).
23. Stafford MR, Hareendran A, DS Ng-Mak, et al. EQ-5DTM-derived utility values for different levels of migraine severity from a UK sample of migraineurs. *Health Qual Life Outcomes*. 2012;10:65. DOI: [10.1186/1477-7525-10-65](https://doi.org/10.1186/1477-7525-10-65).
24. Spierings ELH, Ning X, Ramirez Campos V, et al. Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study. *Headache*. 2021;61:1376–86.
25. Barbanti P, Goadsby PJ, Lambru G, et al. Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study. *J Headache Pain*. 2022;23:1–10. DOI: [10.1186/s10194-022-01521-w](https://doi.org/10.1186/s10194-022-01521-w).
26. Caronna E, Gallardo VJ, Alpuente A, et al. Epidemiology, work and economic impact of migraine in a large hospital cohort: time to raise awareness and promote sustainability. *J Neurol*. 2022;269:1456–62.
27. Sumelahti ML, Sumanen M, Sumanen MS, et al. My migraine voice survey: disease impact on healthcare resource utilization, personal and working life in Finland. *J Headache Pain*. 2020;21:1–11. DOI: [10.1186/s10194-020-01185-4](https://doi.org/10.1186/s10194-020-01185-4).
28. Zhang W, Bansback N, Boonen A, et al. Development of a composite questionnaire, the valuation of lost productivity, to value productivity losses: application in rheumatoid arthritis. *Value Health*. 2012;15:46–54.
29. Tian P, Xu G, Han C, et al. Effects of paradigm color and screen brightness on visual fatigue in light environment of night based on eye tracker and EEG acquisition equipment. *Ah S Sens*. 2022;22. DOI: [10.3390/s22114082](https://doi.org/10.3390/s22114082).
30. Noseda R, Bernstein CA, Nir RR, et al. Migraine photophobia originating in cone-driven retinal pathways. *Brain*. 2016;139:1971–86.
31. Choi JY, Oh K, Kim BJ, et al. Usefulness of a photophobia questionnaire in patients with migraine. *Cephalalgia*. 2009;29:953–9.
32. von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol*. 2008;61:344–9.
33. Stewart WF, Lipton RB, Dowson AJ, et al. Development and testing of the migraine disability assessment (MIDAS) questionnaire to assess headache-related disability. *Neurology*. 2001;56:S20–S28.
34. Zhang W, Bansback N, Kopec J, et al. Measuring time input loss among patients with rheumatoid arthritis: validity and reliability of the valuation of lost productivity questionnaire. *J Occup Environ Med*. 2011;53:530–6.
35. Zhang W, Li KH, Gobis B, et al. Work productivity losses and associated risk factors among university employees in the CAMMPUS wellness program. *J Occup Environ Med*. 2020;62:25–9.
36. Zhang W, Sun H, Gelfand A, et al. Working from home during the COVID-19 pandemic: the association with work productivity loss among patients and caregivers. *J Occup Environ Med*. 2022;64:E677–E684.
37. Rodriguez Llorian E, Zhang W, Khakban A, et al. Productivity loss among people with early multiple sclerosis: a Canadian study. *Mult Scler J*. 2022;28:1414–23.
38. Gelfand A, Sou J, Sawatzky R, et al. Valuation of lost productivity in caregivers: a validation study, Epub ahead of print, *Front Psychol*. 2021;12. DOI: [10.3389/fpsyg.2021](https://doi.org/10.3389/fpsyg.2021).
39. Zhang W, Bansback N, Boonen A, Young A, Singh A, Anis AH. Validity of the work productivity and activity impairment questionnaire-general health version in patients with rheumatoid arthritis. *Arthritis Res Ther*. 2010;12:1–7.
40. Reilly MC, Zbrozek AS, Duker EM. The validity and reproducibility of a work productivity and activity impairment instrument. *Pharmacoeconomics*. 1993;4:353–65.
41. Buse D C, Manack A, Serrano D, Turkel C, Lipton R B. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. *J Neurol Neurosurg Psychiatry*. 2010;81:428–32.
42. Zhang W, Sun H. How to analyze work productivity loss due to health problems in randomized controlled trials? A simulation study. *BMC Med Res Methodol*. 2021;21:1–11. DOI: [10.1186/s12874-021-01330-w](https://doi.org/10.1186/s12874-021-01330-w).
43. Domingues RB, Picon IS, VESCOVi J, et al. Assessment of work productivity and activity impairment (WPAI) questionnaire for migraine with the help of a smartphone app. *Arq Neuropsiquiatr*. 2020;78:468–72.
44. Parikh SK, Kempner J, Young WB. Stigma and migraine: developing effective interventions. *Curr Pain Headache R*. 2021;25:1–10. DOI: [10.1007/s11916-021-00982-z](https://doi.org/10.1007/s11916-021-00982-z).
45. Parikh SK, Young WB. Migraine: stigma in society. *Curr Pain and Headache R*. 2019;23:1–6. DOI: [10.1007/s11916-019-0743-7](https://doi.org/10.1007/s11916-019-0743-7).
46. Begasse de Dhaem O, Sakai F. Migraine in the workplace. *eNeurologicalSci*. 2022;1:100408. DOI: [10.1016/j.ensci.2022.100408](https://doi.org/10.1016/j.ensci.2022.100408).
47. Shimizu T, Sakai F, Miyake H, et al. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. *J Headache Pain*. 2021;22:29. DOI: [10.1186/s10194-021-01243-5](https://doi.org/10.1186/s10194-021-01243-5).
48. Vicente-Herrero T, Burke TA, Laínez MJA. The impact of a worksite migraine intervention program on work productivity, productivity costs, and non-workplace impairment among spanish postal service employees from an employer perspective. *Curr Med Res Opin*. 2004;20:1805–14.
49. Begasse de Dhaem O. Migraines are a serious problem. Employers can help. *Harvard Bus Rev*. 2021. Available at: <https://hbr.org/2021/02/migraines-are-a-serious-problem-employers-can-help>. Accessed March 6, 2024.
50. Begasse de Dhaem O, Gharedaghi MH, Bain P, Hettie G, Loder E, Burch R. Identification of work accommodations and interventions associated with work productivity in adults with migraine: a scoping review. *Cephalalgia*. 2021;41:760–73.
51. Pinquart M, Sörensen S. Differences between caregivers and noncaregivers in psychological health and physical health: a meta-analysis. *Psychol Aging*. 2003;18:250–67.
52. Seedat S, Rondon M. Women's wellbeing and the burden of unpaid work. *BMJ*. 2021;374:n1972. DOI: [10.1136/bmj.n1972](https://doi.org/10.1136/bmj.n1972).
53. Ferrant G, Pesando M, Nowacka K. *Unpaid Care Work: The Missing Link in the Analysis of Gender Gaps in Labour Outcomes*. Paris: OECD; 2014.
54. Nicolas PV, Aikaterini P, Tomas B, et al. Burden of migraine in Europe using self-reported digital diary data from the migraine buddy application. *Neurol Ther*. 2018;7:321–32.
55. Tepper SJ, Ailani J, Ford JH, et al. Effects of Galcanezumab on health-related quality of life and disability in patients with previous failure of 2–4 migraine preventive medication categories: results from a phase IIIb randomized, placebo-controlled, multicenter clinical trial (CONQUER). *Clin Drug Investig*. 2022;42:263–75.
56. Ford J, Tassorelli C, Leroux E, et al. Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN). *Qual Life Res*. 2021;30:105–15.
57. Schulman EA, Cady RK, Henry D, et al. Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. *Mayo Clin Proc*. 2000;75:782–9. DOI: [10.4065/75.8.782](https://doi.org/10.4065/75.8.782).
58. Miller DW, Martin BC, Loo CM. Sumatriptan and lost productivity time: a time series analysis of diary data. *Clin Ther*. 1996;18:1263–75.
59. Cady RC, Ryan R, Jhingran P, et al. Sumatriptan injection reduces productivity loss during a migraine attack results of a double-blind, placebo-controlled trial. *Arch Intern Med*. 1998;158:1013–8. DOI: [10.1001/archinte.158.9.1013](https://doi.org/10.1001/archinte.158.9.1013).
60. Zobdeh F, ben Kraiem A, Attwood MM, et al. Pharmacological treatment of migraine: drug classes, mechanisms of action, clinical trials and new treatments. *Brit J Pharmacol*. 2021;178:4588–607.
61. Zhang W, Bansback N, Anis AH. Measuring and valuing productivity loss due to poor health: a critical review. *Soc Sci Med*. 2011;72:185–92.
62. Doane MJ, Gupta S, Vo P, et al. Associations between headache-free days and patient-reported outcomes among migraine patients: a cross-sectional analysis of survey data in Europe. *Pain Therapy*. 2019;8:203–16.